These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 12176808)

  • 41. Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone.
    Proudman SM; Conaghan PG; Richardson C; Griffiths B; Green MJ; McGonagle D; Wakefield RJ; Reece RJ; Miles S; Adebajo A; Gough A; Helliwell P; Martin M; Huston G; Pease C; Veale DJ; Isaacs J; van der Heijde DM; Emery P
    Arthritis Rheum; 2000 Aug; 43(8):1809-19. PubMed ID: 10943871
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
    Saougou I; Markatseli TE; Papagoras C; Voulgari PV; Alamanos Y; Drosos AA
    Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapy.
    Mori S
    Mod Rheumatol; 2007; 17(2):83-91. PubMed ID: 17437161
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
    Lequerré T; Jouen F; Brazier M; Clayssens S; Klemmer N; Ménard JF; Mejjad O; Daragon A; Tron F; Le Loët X; Vittecoq O
    Rheumatology (Oxford); 2007 Mar; 46(3):446-53. PubMed ID: 16899502
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combination therapy of the chimeric monoclonal anti-tumor necrosis factor alpha antibody (infliximab) with methotrexate in patients with rheumatoid arthritis.
    Antoni C; Kalden JR
    Clin Exp Rheumatol; 1999; 17(6 Suppl 18):S73-7. PubMed ID: 10589362
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Therapy of refractory rheumatoid arthritis. Cyclosporin and methotrexate combination].
    Danieli MG; Fratini M; Rossetti L; Giovagnoni A; Amici F; Danieli G
    Recenti Prog Med; 1998 Jan; 89(1):7-13. PubMed ID: 9549386
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.
    Maini RN; Taylor PC; Szechinski J; Pavelka K; Bröll J; Balint G; Emery P; Raemen F; Petersen J; Smolen J; Thomson D; Kishimoto T;
    Arthritis Rheum; 2006 Sep; 54(9):2817-29. PubMed ID: 16947782
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Infliximab in active early rheumatoid arthritis.
    Breedveld FC; Emery P; Keystone E; Patel K; Furst DE; Kalden JR; St Clair EW; Weisman M; Smolen J; Lipsky PE; Maini RN
    Ann Rheum Dis; 2004 Feb; 63(2):149-55. PubMed ID: 14722203
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons for discontinuation of treatment.
    Levälampi T; Korpela M; Vuolteenaho K; Moilanen E
    Scand J Rheumatol; 2008; 37(1):6-12. PubMed ID: 18189188
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.
    Kremer J; Ritchlin C; Mendelsohn A; Baker D; Kim L; Xu Z; Han J; Taylor P
    Arthritis Rheum; 2010 Apr; 62(4):917-28. PubMed ID: 20131276
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Evaluation of remicade efficiency for the treatment of rheumatoid arthritis].
    Sultanova TZh
    Lik Sprava; 2010; (1-2):78-82. PubMed ID: 20608030
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Infliximab treatment reduces the serum levels of interleukin-23 in patients with rheumatoid arthritis.
    Kageyama Y; Kobayashi H; Kato N
    Mod Rheumatol; 2009; 19(6):657-62. PubMed ID: 19685204
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM).
    Yamanaka H; Tanaka Y; Sekiguchi N; Inoue E; Saito K; Kameda H; Iikuni N; Nawata M; Amano K; Shinozaki M; Takeuchi T
    Mod Rheumatol; 2007; 17(1):28-32. PubMed ID: 17278019
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis.
    Sarzi-Puttini P; D'Ingianna E; Fumagalli M; Scarpellini M; Fiorini T; Chérié-Lignière EL; Panni B; Fiorentini F; Corbelli V; Beyene NB; Mastaglio C; Severi C; Locati M; Cazzola M; Menozzi G; Monti G; Saccardo F; Alfieri G; Atzeni F
    Rheumatol Int; 2005 Jan; 25(1):15-22. PubMed ID: 14530867
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combination treatment with infliximab and leflunomide in patients with active rheumatoid arthritis: safety and efficacy in an open-label clinical trial.
    Kalden JR; Nüsslein HG; Wollenhaupt J; Burmester GR; Krüger K; Antoni C
    Clin Exp Rheumatol; 2008; 26(5):834-40. PubMed ID: 19032816
    [TBL] [Abstract][Full Text] [Related]  

  • 57. IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis.
    Visvanathan S; Wagner C; Smolen J; St Clair EW; Hegedus R; Baker D; Keenan G
    Arthritis Rheum; 2006 Sep; 54(9):2840-4. PubMed ID: 16948115
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure.
    Hambardzumyan K; Saevarsdottir S; Forslind K; Petersson IF; Wallman JK; Ernestam S; Bolce RJ; van Vollenhoven RF
    Arthritis Rheumatol; 2017 May; 69(5):953-963. PubMed ID: 27992691
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis.
    Chen DY; Chou SJ; Hsieh TY; Chen YH; Chen HH; Hsieh CW; Lan JL
    J Formos Med Assoc; 2009 Apr; 108(4):310-9. PubMed ID: 19369178
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predictors of infusion reactions during infliximab treatment in patients with arthritis.
    Kapetanovic MC; Larsson L; Truedsson L; Sturfelt G; Saxne T; Geborek P
    Arthritis Res Ther; 2006; 8(4):R131. PubMed ID: 16869978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.